Patents by Inventor Roger AOKI

Roger AOKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins
    Patent number: 11248219
    Abstract: Single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site; a translocation domain; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: February 15, 2022
    Assignees: Ipsen Bioinnovation Limited, Allergan, Inc.
    Inventors: Peter James, Keith Foster, John Chaddock, Roger Aoki, Lance Steward, Joseph Francis
  • FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATING PAIN
    Publication number: 20190309277
    Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent (eg clostridial neurotoxin L-chain or IgA protease); a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent (eg GALR1, GALR2, or GALR3 receptor); a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent (eg HN domain of clostridial neurotoxin); a first spacer located between the non-cytotoxic protease and the prote
    Type: Application
    Filed: May 20, 2019
    Publication date: October 10, 2019
    Applicants: IPSEN BIOINNOVATION LIMITED, ALLERGAN, INC.
    Inventors: Peter JAMES, Keith FOSTER, John CHADDOCK, Roger AOKI, Lance STEWARD